Profile data is unavailable for this security.
About the company
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
- Revenue in USD (TTM)10.50m
- Net income in USD-111.77m
- Incorporated2016
- Employees131.00
- LocationPrelude Therapeutics Inc175 Innovation BoulevardWILMINGTON 19805United StatesUSA
- Phone+1 (302) 467-1280
- Fax+1 (302) 658-3989
- Websitehttps://preludetx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -67.51m | 132.70m | 28.00 | -- | 1.03 | -- | -- | -5.51 | -5.51 | 0.00 | 7.35 | 0.00 | -- | -- | 0.00 | -49.34 | -69.78 | -55.11 | -97.84 | -- | -- | -- | -5,894.85 | -- | -- | 0.00 | -- | -- | -- | 9.85 | -- | -- | -- |
| Unicycive Therapeutics Inc | 0.00 | -33.47m | 133.25m | 22.00 | -- | 3.45 | -- | -- | -2.85 | -2.85 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -74.93 | -188.44 | -101.88 | -723.53 | -- | -- | -- | -6,003.20 | -- | -- | 0.00 | -- | -100.00 | -- | -20.42 | -- | -- | -- |
| vTv Therapeutics Inc | 17.00k | -23.47m | 133.39m | 23.00 | -- | 1.89 | -- | 7,846.40 | -3.32 | -3.32 | 0.0024 | 17.91 | 0.0002 | -- | -- | 739.13 | -39.79 | -96.30 | -46.08 | -- | -- | -- | -166,935.30 | -775.06 | -- | -- | 0.0046 | -- | -- | -18.12 | 8.83 | -- | -- | -- |
| Spero Therapeutics Inc | 40.55m | -43.84m | 134.65m | 32.00 | -- | 5.08 | -- | 3.32 | -0.7949 | -0.7949 | 0.7299 | 0.4705 | 0.4283 | -- | 1.45 | 1,267,156.00 | -46.31 | -35.16 | -69.26 | -42.63 | -- | -- | -108.11 | -111.75 | -- | -- | 0.00 | -- | -53.77 | 21.46 | -400.65 | -- | -- | -- |
| Vaxart Inc | 148.20m | -50.70m | 135.88m | 105.00 | -- | 4.84 | -- | 0.9168 | -0.2222 | -0.2222 | 0.6495 | 0.1169 | 0.789 | -- | 3.31 | 1,411,467.00 | -26.99 | -49.90 | -80.48 | -58.33 | -- | -- | -34.21 | -875.06 | -- | -31.43 | 0.1161 | -- | 288.94 | 23.82 | 18.82 | -- | -8.21 | -- |
| Sangamo Therapeutics Inc | 32.88m | -108.91m | 138.20m | 183.00 | -- | 19.96 | -- | 4.20 | -0.4428 | -0.4428 | 0.1326 | 0.0194 | 0.3289 | -- | 5.97 | 179,644.80 | -108.96 | -30.73 | -204.29 | -37.33 | -- | -- | -331.28 | -147.59 | -- | -- | 0.00 | -- | -67.20 | -10.81 | 62.01 | -- | -58.10 | -- |
| HST Global Inc | 0.00 | -212.63k | 139.70m | 1.00 | -- | 8.48 | -- | -- | -0.0107 | -0.0107 | 0.00 | 0.1167 | 0.00 | -- | -- | -- | -6.87 | -27.80 | -8.09 | -60.19 | -- | -- | -- | -- | -- | -107.48 | 0.0433 | -- | -- | -- | -45.42 | -- | -- | -- |
| Nkarta Inc | 0.00 | -102.61m | 139.93m | 105.00 | -- | 0.4141 | -- | -- | -1.39 | -1.39 | 0.00 | 4.76 | 0.00 | -- | -- | 0.00 | -21.39 | -29.78 | -22.36 | -31.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.41 | -- | 17.99 | -- |
| Prelude Therapeutics Inc | 10.50m | -111.77m | 140.19m | 131.00 | -- | 2.16 | -- | 13.35 | -1.47 | -1.47 | 0.1382 | 1.03 | 0.0719 | -- | -- | 80,152.67 | -76.56 | -47.36 | -88.86 | -51.44 | -- | -- | -1,064.50 | -7,615.23 | -- | -- | 0.00 | -- | -- | -- | -4.38 | -- | -0.4137 | -- |
| Tenaya Therapeutics Inc | 0.00 | -94.26m | 141.07m | 97.00 | -- | 1.30 | -- | -- | -0.7875 | -0.7875 | 0.00 | 0.5061 | 0.00 | -- | -- | 0.00 | -76.77 | -47.44 | -87.21 | -51.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.44 | -- | -18.92 | -- |
| Fate Therapeutics Inc | 7.14m | -156.09m | 144.19m | 181.00 | -- | 0.616 | -- | 20.20 | -1.32 | -1.32 | 0.0603 | 2.03 | 0.017 | -- | 2.30 | 39,430.94 | -37.23 | -32.44 | -40.38 | -36.57 | -- | -- | -2,187.11 | -389.06 | -- | -- | 0.00 | -- | -78.55 | 5.00 | -15.74 | -- | -37.07 | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -58.01m | 144.79m | 33.00 | -- | 7.06 | -- | -- | -0.8938 | -0.8938 | 0.00 | 0.2407 | 0.00 | -- | -- | 0.00 | -68.07 | -48.63 | -75.01 | -52.10 | -- | -- | -- | -1,201.96 | -- | -73.28 | 0.7327 | -- | -100.00 | -- | 30.44 | -- | -39.67 | -- |
| Connect Biopharma Holdings Ltd (ADR) | 762.00k | -50.77m | 145.35m | 62.00 | -- | 2.62 | -- | 190.75 | -0.9144 | -0.9144 | 0.0137 | 0.9926 | -- | -- | -- | 12,290.32 | -- | -61.12 | -- | -66.78 | -- | -- | -6,662.99 | -1,963.00 | -- | -- | 0.00 | -- | -- | -- | 74.84 | -- | 37.04 | -- |
| Microbot Medical Inc | 0.00 | -13.07m | 145.73m | 21.00 | -- | 1.83 | -- | -- | -0.4513 | -0.4513 | 0.00 | 1.19 | 0.00 | -- | -- | 0.00 | -30.06 | -67.69 | -31.62 | -80.15 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.55 | -- | -35.03 | -- |
| Caribou Biosciences Inc | 9.30m | -157.13m | 147.68m | 147.00 | -- | 1.04 | -- | 15.89 | -1.70 | -1.70 | 0.1004 | 1.52 | 0.0345 | -- | 6.57 | 63,231.29 | -58.27 | -30.69 | -65.59 | -33.30 | -- | -- | -1,690.45 | -562.81 | -- | -- | 0.00 | -- | -71.01 | 11.54 | -46.08 | -- | 40.73 | -- |
Data as of Feb 13 2026. Currency figures normalised to Prelude Therapeutics Inc's reporting currency: US Dollar USD
35.13%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 30 Sep 2025 | 10.12m | 23.13% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.25m | 2.86% |
| Millennium Management LLCas of 30 Sep 2025 | 1.15m | 2.62% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 876.34k | 2.00% |
| Acadian Asset Management LLCas of 31 Dec 2025 | 535.70k | 1.22% |
| OrbiMed Advisors LLCas of 31 Jan 2026 | 346.50k | 0.79% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2025 | 276.12k | 0.63% |
| Marshall Wace LLPas of 31 Dec 2025 | 273.88k | 0.63% |
| Geode Capital Management LLCas of 31 Dec 2025 | 272.89k | 0.62% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 271.30k | 0.62% |
More ▼
Data from 30 Sep 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
